Bacillus coagulans SNZ 1969®, a natural spore forming probiotic strain with five decades history of use and over 30 human studies across age groups found to be effective in managing IBS symptoms, demonstrates the latest clinical study.  This study is unique as it covers both the IBS-D and IBS-C groups with larger number of subjects.

Irritable bowel syndrome (IBS) is one of the most common disorders of gut-brain interaction, estimated to affect around 11% people globally.  The outcome of this study will be significant to supplement manufacturers as it can help design products to address consumer need for managing IBS symptoms with a scientifically studied probiotic strain.

In a randomized, double blind, placebo-controlled study1, probiotic potential (efficacy and safety) of SNZ 1969® has been studied in patients with constipation predominant irritable bowel syndrome (IBS-C) and diarrhea predominant irritable bowel syndrome (IBS-D).  Reduction in the GSRS-IBS score was greater in the treatment group (39.78%) compared to the placebo group (2.42%). Consistent reductions in the GSRS-IBS score also seen in patients with IBS-D from baseline (62.5±3.9) to day 75 (34.45±3.53) (p<0.0001) after treatment with SNZ 1969®.  The study showed most patients (90%) with IBS-C and 100% with IBS-D responded to SNZ 1969® as compared to no responders treated with placebo, p<0.0001.  SNZ 1969® was found to be safe and effective alternative to therapeutic option for IBS patients as it alleviates IBS-associated clinical symptoms and improves the quality of life as compared to placebo.

This study was conduct at Apollo Hospitals, Hyderabad, India and published in the International Journal of Basic & Clinical Pharmacology.

The same strain has been studied earlier for gastrointestinal discomfort, intestinal motility and intermittent constipation among health subjects.  GI discomfort study2 showed an improvement in total SODA scores, including specific symptoms such as burping/belching, bloating, heartburn, passing gas, nausea, bad breath, and sour taste compared with placebo.  Intestinal motility3 study concluded that SNZ 1969® reaches the colon intact and ameliorates intestinal motility and gut microbiota composition by enhancing lactobacillales and diminishing synergistales.  With the latest IBS study, the overall digestive health positioning of SNZ 1969® has been bolstered and made SNZ 1969® an ultimate option for food and supplement manufacturers around the globe.

About Sanzyme Biologics

Sanzyme Biologics was incorporated in 1969 as Uni-Sankyo and was the first company to manufacture and sell probiotics in the Indian market.  Over the last five decades Sanzyme Biologics established its strength in probiotics by developing scientifically studied and well-documented probiotic strains, pioneered their applications beyond human health into aqua, veterinary, poultry and bioremediation.  Sanzyme Biologics has market presence in over 40 countries across the globe.